Verastem, Inc.
HealthcareNASDAQ:VSTM · NASDAQ Global Market
+$0.17 today
Vol 1.60M · Avg 2.34M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-366.2%
avg -247.7%
ROIC
-97.4%
avg -80.7%
ROA
-85.0%
avg -68.9%
Analysis
ROA is currently the strongest return metric at -85.0% versus its period average of -68.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Daniel W. Paterson | President, Chief Executive Officer & Director | $1.24M | — | 65 | $612,113.00 | 0.88% |
Michael Glen Kauffman | President of Development & Director | $930,000.00 | — | 63 | $108,000.00 | 0.16% |
Daniel Calkins | Chief Financial Officer | $526,150.00 | — | 38 | $121,327.00 | 0.18% |
Jonathan Pachter | Chief Scientific Officer | $238,176.00 | — | 68 | $62,249.00 | 0.09% |
Michelle Detwiler | Co-Founder | — | — | 50 | $52,666.00 | 0.08% |
Colleen Mockbee | Global Head of Regulatory Affairs & Development | — | — | — | — | — |
Julissa Viana | Vice President of Corporate Communications & Investor Relations | — | — | — | — | — |
John Hayslip | Chief Medical Officer | — | — | 49 | $52,666.00 | 0.08% |
Mark J. Wanda | Senior VP of Legal & Chief Compliance Officer | — | — | — | — | — |
Nathan Sanburn | Chief Business Officer | — | — | — | — | — |
Lori Horvat | Executive Vice President of Portfolio Strategy & Operations | — | — | — | — | — |
Robert A. Weinberg | Co-Founder & Chair of Scientific Advisory Board | — | — | — | $44,333.00 | 0.06% |
Cathy Carew | Chief Organizational Effectiveness Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
39
$815,983.96
Net Sentiment
$815,983.96
Net selling
Most Active
Paterson Dan
24 transactions
1–10 of 39
Analysis
Insiders reported 0 buys worth $0.00 and 39 sells worth $815,983.96 over the last 12 months. That adds up to net selling of $815,983.96. Paterson Dan was the most active insider with 24 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
$1.44B
MoonLake Immunotherapeutics
NASDAQ:MLTX
$1.38B
Absci Corporation
NASDAQ:ABSI
$1.06B
Ventyx Biosciences, Inc.
VTYX
$1.00B
Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
$1.00B
Olema Pharmaceuticals, Inc.
NASDAQ:OLMA
$862.12M
4D Molecular Therapeutics, Inc.
NASDAQ:FDMT
$461.60M
Prothena Corporation plc
NASDAQ:PRTA
$431.91M
REGENXBIO Inc.
NASDAQ:RGNX
$344.31M
Gossamer Bio, Inc.
GOSS
$38.00M
Who manages VSTM?
Verastem, Inc. (VSTM) lists 13 active executives. The top listed executive is Daniel W. Paterson, President, Chief Executive Officer & Director.
Are VSTM insiders buying or selling?
Recent insider activity shows net selling of $3.73M.
Explore More
Continue the stock analysis
Jump to another research area for this company.